Company intelligence / Profile preview
7TM Pharma
Denmark7tm.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company had several drug candidates in development for metabolic disorders and obesity, including TM30339 (a Y4 selective agonist) and TM38837 (a peripherally acting CB1 antagonist). As of 2025, most programs appear to be discontinued or pending.
- Therapeutic areas
- PulmonologyEndocrinologyCardiovascularMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
OSI Pharmaceuticals
Beyond the preview
Go deeper on 7TM Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 7TM Pharma.